Cargando…
Pharmacological rationale for antihypertensive drug choice on COVID‐19–affected patients: ACEI/ARB might not increase their susceptibility
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537110/ https://www.ncbi.nlm.nih.gov/pubmed/32942339 http://dx.doi.org/10.1111/jcmm.15850 |
| _version_ | 1783590642309398528 |
|---|---|
| author | Zhao, Hong‐Jin Yang, Xiao‐Mei Wang, Ai‐Hong Li, Yan |
| author_facet | Zhao, Hong‐Jin Yang, Xiao‐Mei Wang, Ai‐Hong Li, Yan |
| author_sort | Zhao, Hong‐Jin |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7537110 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-75371102020-10-07 Pharmacological rationale for antihypertensive drug choice on COVID‐19–affected patients: ACEI/ARB might not increase their susceptibility Zhao, Hong‐Jin Yang, Xiao‐Mei Wang, Ai‐Hong Li, Yan J Cell Mol Med Letter to the Editor John Wiley and Sons Inc. 2020-09-17 2020-11 /pmc/articles/PMC7537110/ /pubmed/32942339 http://dx.doi.org/10.1111/jcmm.15850 Text en © 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Letter to the Editor Zhao, Hong‐Jin Yang, Xiao‐Mei Wang, Ai‐Hong Li, Yan Pharmacological rationale for antihypertensive drug choice on COVID‐19–affected patients: ACEI/ARB might not increase their susceptibility |
| title | Pharmacological rationale for antihypertensive drug choice on COVID‐19–affected patients: ACEI/ARB might not increase their susceptibility |
| title_full | Pharmacological rationale for antihypertensive drug choice on COVID‐19–affected patients: ACEI/ARB might not increase their susceptibility |
| title_fullStr | Pharmacological rationale for antihypertensive drug choice on COVID‐19–affected patients: ACEI/ARB might not increase their susceptibility |
| title_full_unstemmed | Pharmacological rationale for antihypertensive drug choice on COVID‐19–affected patients: ACEI/ARB might not increase their susceptibility |
| title_short | Pharmacological rationale for antihypertensive drug choice on COVID‐19–affected patients: ACEI/ARB might not increase their susceptibility |
| title_sort | pharmacological rationale for antihypertensive drug choice on covid‐19–affected patients: acei/arb might not increase their susceptibility |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537110/ https://www.ncbi.nlm.nih.gov/pubmed/32942339 http://dx.doi.org/10.1111/jcmm.15850 |
| work_keys_str_mv | AT zhaohongjin pharmacologicalrationaleforantihypertensivedrugchoiceoncovid19affectedpatientsaceiarbmightnotincreasetheirsusceptibility AT yangxiaomei pharmacologicalrationaleforantihypertensivedrugchoiceoncovid19affectedpatientsaceiarbmightnotincreasetheirsusceptibility AT wangaihong pharmacologicalrationaleforantihypertensivedrugchoiceoncovid19affectedpatientsaceiarbmightnotincreasetheirsusceptibility AT liyan pharmacologicalrationaleforantihypertensivedrugchoiceoncovid19affectedpatientsaceiarbmightnotincreasetheirsusceptibility |